Author:
Zientek Michael,Youdim Kuresh
Reference41 articles.
1. Smith CC, Bennett PM, Pearce HM, Harrison PI, Reynolds DJ, Aronson JK, Grahame-Smith DG (1996) Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol 42:423–9
2. Issa AM, Phillips KA, Van Bebber S, Nidmarthy HG, Lasser KE, Haas JS, Alldredge BK, Wachter RM, Bates DW (2007) Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. Curr Drug Saf 2:177–185
3. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metabol Dispos 31:815–32
4. Huang S, Stifano T (2006) C.f.D.E.a.R. (CDER), C.f.B.E.a.R. (CBER) (ed) Draft guidance for industry: drug interaction studies—study design, data analysis, and implications for dosing and labeling. U.S. Department of Health and Human Services Food and Drug Administration.
5. Tucker G, Houston B, Huang S (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential—toward a consensus. Pharmaceut Res V18:1071–1080
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献